Irina Chuckowree
UCB Pharma (United Kingdom)(GB)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Protein Kinase Regulation and GTPase Signaling, Biochemical and Molecular Research, Crystallization and Solubility Studies, X-ray Diffraction in Crystallography
Most-Cited Works
- → The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer(2008)741 cited
- → Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941(2009)271 cited
- → Small molecule induced reactivation of mutant p53 in cancer cells(2013)227 cited
- → Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer(2011)215 cited
- → Novel Angular Benzophenazines: Dual Topoisomerase I and Topoisomerase II Inhibitors as Potential Anticancer Agents(2002)133 cited
- → Discovery of (Thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer(2010)131 cited
- → Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor(2010)88 cited
- → Studies on Pyrrolopyrimidines as Selective Inhibitors of Multidrug-Resistance- Associated Protein in Multidrug Resistance(2004)79 cited
- → Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion(2021)68 cited
- → Design and Synthesis of New Templates Derived from Pyrrolopyrimidine as Selective Multidrug-Resistance-Associated Protein Inhibitors in Multidrug Resistance(2004)44 cited